Literature DB >> 33376114

PLK1 Induces Chromosomal Instability and Overrides Cell-Cycle Checkpoints to Drive Tumorigenesis.

Lilia Gheghiani1, Lei Wang1, Youwei Zhang1, Xavier T R Moore2, Jinglei Zhang1, Steven C Smith3, Yijun Tian4, Liang Wang4, Kristi Turner3, Colleen K Jackson-Cook1,3, Nitai D Mukhopadhyay5, Zheng Fu6.   

Abstract

Polo-like kinase 1 (PLK1) is an essential cell-cycle regulator that is frequently overexpressed in various human cancers. To determine whether Plk1 overexpression drives tumorigenesis, we established transgenic mouse lines that ubiquitously express increased levels of Plk1. High Plk1 levels were a driving force for different types of spontaneous tumors. Increased Plk1 levels resulted in multiple defects in mitosis and cytokinesis, supernumerary centrosomes, and compromised cell-cycle checkpoints, allowing accumulation of chromosomal instability (CIN), which resulted in aneuploidy and tumor formation. Clinically, higher expression of PLK1 positively associated with an increase in genome-wide copy-number alterations in multiple human cancers. This study provides in vivo evidence that aberrant expression of PLK1 triggers CIN and tumorigenesis and highlights potential therapeutic opportunities for CIN-positive cancers. SIGNIFICANCE: These findings establish roles for PLK1 as a potent proto-oncogene and a CIN gene and provide insights for the development of effective treatment regimens across PLK1-overexpressing and CIN-positive cancers. ©2020 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33376114      PMCID: PMC8026515          DOI: 10.1158/0008-5472.CAN-20-1377

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   13.312


  50 in total

1.  CDC5 and CKII control adaptation to the yeast DNA damage checkpoint.

Authors:  D P Toczyski; D J Galgoczy; L H Hartwell
Journal:  Cell       Date:  1997-09-19       Impact factor: 41.582

Review 2.  The same, only different - DNA damage checkpoints and their reversal throughout the cell cycle.

Authors:  Indra A Shaltiel; Lenno Krenning; Wytse Bruinsma; René H Medema
Journal:  J Cell Sci       Date:  2015-01-20       Impact factor: 5.285

3.  Whole chromosome instability caused by Bub1 insufficiency drives tumorigenesis through tumor suppressor gene loss of heterozygosity.

Authors:  Darren J Baker; Fang Jin; Karthik B Jeganathan; Jan M van Deursen
Journal:  Cancer Cell       Date:  2009-12-08       Impact factor: 31.743

4.  Polo-like kinase 1 (Plk1) overexpression enhances ionizing radiation-induced cancer formation in mice.

Authors:  Zhiguo Li; Jinghui Liu; Jie Li; Yifan Kong; George Sandusky; Xi Rao; Yunlong Liu; Jun Wan; Xiaoqi Liu
Journal:  J Biol Chem       Date:  2017-09-12       Impact factor: 5.157

Review 5.  Targeting polo-like kinase 1 for cancer therapy.

Authors:  Klaus Strebhardt; Axel Ullrich
Journal:  Nat Rev Cancer       Date:  2006-04       Impact factor: 60.716

6.  The Polyploid State Restricts Hepatocyte Proliferation and Liver Regeneration in Mice.

Authors:  Patrick D Wilkinson; Evan R Delgado; Frances Alencastro; Madeleine P Leek; Nairita Roy; Matthew P Weirich; Elizabeth C Stahl; P Anthony Otero; Maelee I Chen; Whitney K Brown; Andrew W Duncan
Journal:  Hepatology       Date:  2019-02-15       Impact factor: 17.425

7.  Plk1 phosphorylation of orc2 and hbo1 contributes to gemcitabine resistance in pancreatic cancer.

Authors:  Bing Song; X Shawn Liu; Steven J Rice; Shihuan Kuang; Bennett D Elzey; Stephen F Konieczny; Timothy L Ratliff; Tony Hazbun; Elena G Chiorean; Xiaoqi Liu
Journal:  Mol Cancer Ther       Date:  2012-11-27       Impact factor: 6.261

8.  Spatial Separation of Plk1 Phosphorylation and Activity.

Authors:  Wytse Bruinsma; Melinda Aprelia; Jolanda Kool; Libor Macurek; Arne Lindqvist; René H Medema
Journal:  Front Oncol       Date:  2015-06-10       Impact factor: 6.244

9.  Plk1 overexpression induces chromosomal instability and suppresses tumor development.

Authors:  Guillermo de Cárcer; Sharavan Vishaan Venkateswaran; Lorena Salgueiro; Aicha El Bakkali; Kalman Somogyi; Konstantina Rowald; Pablo Montañés; Manuel Sanclemente; Beatriz Escobar; Alba de Martino; Nicholas McGranahan; Marcos Malumbres; Rocío Sotillo
Journal:  Nat Commun       Date:  2018-08-01       Impact factor: 14.919

10.  PLK1 has tumor-suppressive potential in APC-truncated colon cancer cells.

Authors:  Monika Raab; Mourad Sanhaji; Yves Matthess; Albrecht Hörlin; Ioana Lorenz; Christina Dötsch; Nils Habbe; Oliver Waidmann; Elisabeth Kurunci-Csacsko; Ron Firestein; Sven Becker; Klaus Strebhardt
Journal:  Nat Commun       Date:  2018-03-16       Impact factor: 14.919

View more
  7 in total

Review 1.  The matrix in cancer.

Authors:  Thomas R Cox
Journal:  Nat Rev Cancer       Date:  2021-02-15       Impact factor: 60.716

2.  Targeting Plk1 Sensitizes Pancreatic Cancer to Immune Checkpoint Therapy.

Authors:  Zhuangzhuang Zhang; Lijun Cheng; Jie Li; Qi Qiao; Anju Karki; Derek B Allison; Nuha Shaker; Kunyu Li; Sagar M Utturkar; Nadia M Atallah Lanman; Xiongjian Rao; Piotr Rychahou; Daheng He; Stephen F Konieczny; Chi Wang; Qing Shao; B Mark Evers; Xiaoqi Liu
Journal:  Cancer Res       Date:  2022-10-04       Impact factor: 13.312

3.  CCNB1 promotes the development of hepatocellular carcinoma by mediating DNA replication in the cell cycle.

Authors:  Min-Hua Rong; Jian-Di Li; Lu-Yang Zhong; Yu-Zhen Huang; Juan Chen; Li-Yuan Xie; Rong-Xing Qin; Xiao-Lian He; Zhan-Hui Zhu; Su-Ning Huang; Xian-Guo Zhou
Journal:  Exp Biol Med (Maywood)       Date:  2021-11-07

4.  The Polo-like kinase 1 inhibitor onvansertib represents a relevant treatment for head and neck squamous cell carcinoma resistant to cisplatin and radiotherapy.

Authors:  Anais Hagege; Damien Ambrosetti; Julien Boyer; Alexandre Bozec; Jérôme Doyen; Emmanuel Chamorey; Xingkang He; Isabelle Bourget; Julie Rousset; Esma Saada; Olivia Rastoin; Julien Parola; Frederic Luciano; Yihai Cao; Gilles Pagès; Maeva Dufies
Journal:  Theranostics       Date:  2021-09-21       Impact factor: 11.556

Review 5.  Mitotic protein kinase-driven crosstalk of machineries for mitosis and metastasis.

Authors:  Chang-Hyeon Kim; Da-Eun Kim; Dae-Hoon Kim; Ga-Hong Min; Jung-Won Park; Yeo-Bin Kim; Chang K Sung; Hyungshin Yim
Journal:  Exp Mol Med       Date:  2022-04-04       Impact factor: 12.153

6.  Chromatin Separation Regulators Predict the Prognosis and Immune Microenvironment Estimation in Lung Adenocarcinoma.

Authors:  Zhaoshui Li; Zaiqi Ma; Hong Xue; Ruxin Shen; Kun Qin; Yu Zhang; Xin Zheng; Guodong Zhang
Journal:  Front Genet       Date:  2022-07-08       Impact factor: 4.772

7.  PLK1 Inhibition Induces Immunogenic Cell Death and Enhances Immunity against NSCLC.

Authors:  Jie Zhou; Qifan Yang; Lisen Lu; Zhan Tuo; Zhexing Shou; Jing Cheng
Journal:  Int J Med Sci       Date:  2021-08-19       Impact factor: 3.738

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.